U.S. flag

An official website of the United States government

Display Settings:

Items per page

PMC Full-Text Search Results

Items: 6

2.

Figure. From: Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.

Fig 6 Forest plot showing meta-analyses of published, unpublished, and all trials. Publication bias (right column) is presented as the ratio of odds ratios of published results versus overall results. The extent of publication bias is expressed as percentage change between the analysis of published trials only and the analysis of all trials (that is, publication bias=100×(ORpublished data/ORtotal data–1)). *Fluoxetine controlled studies only

Dirk Eyding, et al. BMJ. 2010;341:c4737.
3.

Figure. From: Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.

Fig 4 Forest plot showing meta-analyses of rates of patients with at least one adverse event and rates of withdrawals owing to adverse events for trials that compared reboxetine with placebo. Empty boxes show published studies and filled boxes show unpublished studies. CI, confidence interval; n, number of patients with event; N, number of patients in treatment group

Dirk Eyding, et al. BMJ. 2010;341:c4737.
4.

Figure. From: Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.

Fig 3 Forest plot showing meta-analyses of remission and response rates for trials that compared reboxetine with selective serotonin reuptake inhibitors (SSRIs; fluoxetine, paroxetine, and citalopram). Empty boxes show published studies and filled boxes show unpublished studies. Empty diamonds show subtotals (individual SSRIs) and filled diamonds show overall totals (all SSRIs). CI, confidence interval; n, number of patients with event; N, number of patients in treatment group

Dirk Eyding, et al. BMJ. 2010;341:c4737.
5.

Figure. From: Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.

Fig 2 Forest plot showing meta-analyses of remission and response rates for trials that compared reboxetine with placebo. Empty boxes show published studies and filled boxes show unpublished studies. Study 091 is not included in the pooled analysis of response of reboxetine versus placebo because of high heterogeneity (see text for details). CI, confidence interval; n, number of patients with event; N, number of patients in treatment group

Dirk Eyding, et al. BMJ. 2010;341:c4737.
6.

Figure. From: Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.

Fig 5 Forest plot showing meta-analyses of rates of patients with at least one adverse event and rates of withdrawals owing to adverse events for trials that compared reboxetine with selective serotonin reuptake inhibitors (SSRIs; fluoxetine and paroxetine). Empty boxes show published studies and filled boxes show unpublished studies. Empty diamonds show subtotals (individual SSRIs) and filled diamonds show overall totals (all SSRIs). CI, confidence interval; n, number of patients with event; N, number of patients in treatment group

Dirk Eyding, et al. BMJ. 2010;341:c4737.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center